
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6007850/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia, 2001, 44, 659-673.	2.9	265
2	Early onset type 2 diabetes: risk factors, clinical impact and management. Therapeutic Advances in Chronic Disease, 2014, 5, 234-244.	1.1	172
3	Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis. Diabetologia, 2016, 59, 44-55.	2.9	155
4	Human Skeletal Muscle Disuse Atrophy: Effects on Muscle Protein Synthesis, Breakdown, and Insulin Resistance—A Qualitative Review. Frontiers in Physiology, 2016, 7, 361.	1.3	140
5	Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochemical Pharmacology, 2002, 63, 993-996.	2.0	80
6	Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes. Archives of Internal Medicine, 2012, 172, 1005-11.	4.3	70
7	Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Scientific Reports, 2019, 9, 5389.	1.6	64
8	Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia, 2003, 46, 288-290.	2.9	59
9	Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1276-1294.	2.9	56
10	Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies. Diabetes Therapy, 2020, 11, 1947-1963.	1.2	55
11	DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2016, 116, 288-298.	1.1	52
12	Relationship between HbA _{1c} and cancer in people with or without diabetes: a systematic review. Diabetic Medicine, 2016, 33, 1013-1025.	1.2	49
13	A Systematic Review of Evidence on the Use of Very Low Calorie Diets in People with Diabetes. Current Diabetes Reviews, 2016, 13, 35-46.	0.6	42
14	Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Research and Care, 2018, 6, e000512.	1.2	37
15	Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Annals of Medicine, 2016, 48, 224-234.	1.5	36
16	Biphasic vs basal bolus insulin regimen in TypeÂ2 diabetes: a systematic review and metaâ€analysis of randomized controlled trials. Diabetic Medicine, 2015, 32, 585-594.	1.2	31
17	Drugâ€Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism. Clinical Pharmacology and Therapeutics, 2016, 99, 390-400.	2.3	30
18	Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart, 2016, 102, 1581-1587.	1.2	29

#	Article	IF	CITATIONS
19	Healthcare Costs and Adherence Associated with Human Regular U-500 Versus High-Dose U-100 Insulin in Patients with Diabets. Endocrine Practice, 2014, 20, 663-670.	1.1	27
20	Physiological Mechanisms of Action of Incretin and Insulin in Regulating Skeletal Muscle Metabolism. Current Diabetes Reviews, 2014, 10, 327-335.	0.6	27
21	Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data. Diabetic Medicine, 2017, 34, 1728-1736.	1.2	24
22	Lower risk of hospitalization for heart failure, kidney disease and death with sodiumâ€glucose coâ€transporterâ€2 inhibitors compared with dipeptidyl peptidaseâ€4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. Diabetes, Obesity and Metabolism, 2021, 23, 2207-2214.	2.2	22
23	Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2010, 12, 865-870.	2.2	21
24	Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. BMJ Open Diabetes Research and Care, 2015, 3, e000074.	1.2	21
25	Tier 3 specialist weight management service and preâ€bariatric multicomponent weight management programmes for adults with obesity living in the UK: A systematic review. Endocrinology, Diabetes and Metabolism, 2019, 2, e00042.	1.0	21
26	Exploring mechanistic links between extracellular branched-chain amino acids and muscle insulin resistance: an in vitro approach. American Journal of Physiology - Cell Physiology, 2020, 319, C1151-C1157.	2.1	20
27	Effectiveness of a Digital Lifestyle Change Program in Obese and Type 2 Diabetes Populations: Service Evaluation of Real-World Data. JMIR Diabetes, 2020, 5, e15189.	0.9	20
28	Genetic polymorphisms of the endocannabinoid system in obesity and diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 382-387.	2.2	17
29	A Novel Dietary Intervention Reduces Circulatory Branched-Chain Amino Acids by 50%: A Pilot Study of Relevance for Obesity and Diabetes. Nutrients, 2021, 13, 95.	1.7	17
30	Protein kinase C-β inhibition and diabetic microangiopathy: effects on endothelial permeability responses in vitro. European Journal of Pharmacology, 2004, 485, 141-144.	1.7	16
31	Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort. American Journal of Nephrology, 2019, 49, 146-155.	1.4	16
32	Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. American Heart Journal, 2018, 196, 18-27.	1.2	15
33	Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation. Current Medical Research and Opinion, 2022, 38, 357-364.	0.9	15
34	Grader agreement, and sensitivity and specificity of digital photography in a community optometry-based diabetic eye screening program. Clinical Ophthalmology, 2014, 8, 1345.	0.9	14
35	Effect of Bariatric Surgery on Cardiovascular Events and Metabolic Outcomes in Obese Patients with Insulin-Treated Type 2 Diabetes: a Retrospective Cohort Study. Obesity Surgery, 2019, 29, 3154-3164.	1.1	14
36	Glucagonâ€like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell, 2020, 19, e13202.	3.0	14

#	Article	IF	CITATIONS
37	Insulin Action in Skeletal Muscle. Annals of the New York Academy of Sciences, 2002, 967, 176-182.	1.8	13
38	Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. Diabetes Research and Clinical Practice, 2016, 121, 69-85.	1,1	13
39	Midâ€Term Remission of Type 2 Diabetes Mellitus After Laparoscopic Roux Enâ€Y Gastric Bypass. World Journal of Surgery, 2016, 40, 2719-2725.	0.8	11
40	Continuous subcutaneous insulin infusion (<scp>CSII</scp>) therapy at Derby Teaching Hospitals: sustained benefits in glucose control. Diabetic Medicine, 2017, 34, 1154-1157.	1.2	11
41	Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovascular Diabetology, 2017, 16, 107.	2.7	11
42	Relationship between HbA1c and all-cause mortality in older patients with insulin-treated type 2 diabetes: results of a large UK Cohort Study. Age and Ageing, 2019, 48, 235-240.	0.7	11
43	Responders to insulin therapy at 18Âmonths in adults with newly diagnosed diabetes: which insulin regimen?. Diabetic Medicine, 2013, 30, e95-100.	1.2	9
44	Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample. Primary Care Diabetes, 2019, 13, 106-112.	0.9	9
45	Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes – exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations. Current Medical Research and Opinion, 2020, 36, 1985-1989.	0.9	9
46	The Effects of Very Low Energy Diets and Low Energy Diets with Exercise Training on Skeletal Muscle Mass: A Narrative Review. Advances in Therapy, 2021, 38, 149-163.	1.3	9
47	Pharmacological hypogonadism impairs molecular transducers of exerciseâ€induced muscle growth in humans. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1134-1150.	2.9	9
48	Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. Expert Review of Endocrinology and Metabolism, 2022, 17, 255-267.	1.2	8
49	A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK. Journal of Medical Economics, 2015, 18, 273-282.	1.0	7
50	Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. Diabetes Technology and Therapeutics, 2016, 18, 85-92.	2.4	7
51	Evaluation of Liver Function Tests and Risk Score Assessment to Screen Patients for Significant Liver Disease Prior to Bariatric and Metabolic Surgery. Obesity Surgery, 2020, 30, 2840-2843.	1.1	7
52	Promoting health and reducing costs: a role for reform of selfâ€monitoring of blood glucose provision within the National Health Service. Diabetic Medicine, 2016, 33, 681-690.	1.2	6
53	Effects of obesity on metabolic and cardiovascular outcomes following insulin initiation in patients with type 2 diabetes. Obesity Research and Clinical Practice, 2018, 12, 72-84.	0.8	6
54	Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database. Obesity Surgery, 2020, 30, 1685-1695.	1.1	6

ISKANDAR

#	Article	IF	CITATIONS
55	Association between insulinâ€induced weight change and CVD mortality: Evidence from a historic cohort study of 18,814 patients in UK primary care. Diabetes/Metabolism Research and Reviews, 2018, 34, e2945.	1.7	6
56	Safety and effectiveness of doâ€itâ€yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes. Diabetic Medicine, 2022, 39, e14793.	1.2	6
57	Insulin action in skeletal muscle: isozyme-specific effects of protein kinase C. Annals of the New York Academy of Sciences, 2002, 967, 176-82.	1.8	6
58	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 676-677.	0.9	5
59	Short-Term Impact of Bariatric Surgery on Best-Corrected Distance Visual Acuity and Diabetic Retinopathy Progression. Obesity Surgery, 2018, 28, 3711-3713.	1.1	5
60	Individual and Combined Relationship between Reduced eGFR and/or Increased Urinary Albumin Excretion Rate with Mortality Risk among Insulin-Treated Patients with Type 2 Diabetes in Routine Practice. Kidney Diseases (Basel, Switzerland), 2019, 5, 91-99.	1.2	5
61	Phenylbutyrate, a branchedâ€chain amino acid keto dehydrogenase activator, promotes branchedâ€chain amino acid metabolism and induces muscle catabolism in C2C12 cells. Experimental Physiology, 2021, 106, 585-592.	0.9	5
62	Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study. Diabetes Therapy, 2015, 6, 213-226.	1.2	4
63	The effect of oral essential amino acids on incretin hormone production in youth and ageing. Endocrinology, Diabetes and Metabolism, 2019, 2, e00085.	1.0	4
64	The metabolic and liver-related outcomes of bariatric surgery in adult patients with insulin-treated type 2 diabetes and nonalcoholic fatty liver disease at high risk of liver fibrosis. Surgery for Obesity and Related Diseases, 2021, 17, 792-798.	1.0	4
65	Indicators of response to exercise training: a systematic review and meta-analysis. BMJ Open, 2021, 11, e044676.	0.8	4
66	Significant reduction in chronic kidney disease progression with sodiumâ€glucose cotransporterâ€2 inhibitors compared to dipeptidyl peptidaseâ€4 inhibitors in adults with type 2 diabetes in a <scp>UK</scp> clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 2138-2147.	2.2	4
67	Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb) Tj E Diabetes Research and Care, 2014, 2, e000021.	TQq1 1 0.78 1.2	84314 rgBT 3
68	Clinical use and efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes – a nationwide evaluation of clinical practice. Current Medical Research and Opinion, 2015, 31, 493-501.	0.9	3
69	Endocannabinoids in aqueous humour of patients with or without diabetes. BMJ Open Ophthalmology, 2020, 5, e000425.	0.8	3
70	The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices. Nephrology Dialysis Transplantation, 2020, 35, 471-477.	0.4	2
71	Effectiveness of the Transformation model, a model of care that integrates diabetes services across primary, secondary and community care: A retrospective study. Diabetic Medicine, 2021, 38, e14504.	1.2	2
72	Demographics, insulin use and clinical targets in type 2 diabetes insulin users: comparison of a local integrated diabetes service vs a <scp>UK</scp> â€wide cohort. Practical Diabetes, 2017, 34, 123-128.	0.1	1

#	Article	IF	CITATIONS
73	Early detection of neonatal sepsis using fourier transformation infrared spectroscopy (FTIR). AIP Conference Proceedings, 2019, , .	0.3	1
74	Sustained reduction in delaying type 1 diabetes with teplizumab. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	1
75	Diabetes specialist nurse pointâ€of are review service: improving clinical outcomes for people with diabetes on emergency wards. Practical Diabetes, 2020, 37, 50-54.	0.1	1
76	Clinical characteristics and patient treatment satisfaction with Humalog U-200 in patients with type 2 diabetes mellitus: an observational study. Journal of Drug Assessment, 2020, 9, 8-12.	1.1	1
77	Novel development of a $co\hat{\epsilon}_{f}$ ormulation of insulin and Amylin. Diabetes Obesity and Metabolism Now, O, , .	0.0	1
78	13 CONTRIBUTORY OF PRECIPITATING FACTORS, COMORBIDITIES AND OUTCOMES IN PATIENT HOSPITALIZED WITH HEART FAILURE AND HYPERTENSION. Journal of Hypertension, 2019, 37, e4.	0.3	0
79	14 EFFECT OF MULTIMORBIDITY ON THE LENGTH OF STAY AMONG HYPERTENSIVE HEART FAILURE INPATIENTS AT SAIFUL ANWAR HOSPITAL. Journal of Hypertension, 2019, 37, e4-e5.	0.3	0
80	ACE and ARB does not increase the risk of dying from COVIDâ€19. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
81	Grip strength can predict type 2 diabetes. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
82	Study dissecting COVIDâ€19 related mortality in people with Type 1 and Type 2 diabetes. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
83	ADA 2020: Dapagliflozin may help reduce onset of type 2 diabetes. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
84	ADA 2020: Telehealth improves glycaemic control among rural diabetes patients. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
85	ADA 2020: FreeStyle Libre system initiation provides dramatic drop in diabetic ketoacidosis rates. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
86	ADA 2020: Ertugliflozin shown to significantly reduce heart failure hospitalization. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
87	Dapagliflozin significantly prolongs survival in CKD patients. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
88	COVIDâ€19: An opportunity to make longâ€ŧerm improvement changes to inpatient diabetes services. Diabetes Obesity and Metabolism Now, 2020, , .	0.0	0
89	699 Pre-Operative Screening and Investigation of Patients with Suspected Non-Alcoholic Fatty Liver Disease Among Bariatric Surgery Patients. British Journal of Surgery, 2021, 108, .	0.1	0
90	Hypoglycaemia in type 2 diabetes treated with preâ€mixed insulin. Diabetic Medicine, 2021, , e14684.	1.2	0

#	Article	IF	CITATIONS
91	Clinical cost evaluation and health benefits of postâ€bariatric intervention for patients with type 2 diabetes living in the <scp>UK</scp> . Clinical Obesity, 2021, 11, e12486.	1.1	Ο
92	Experimental drug shown to reduce adverse effects of Rosiglitazone. Diabetes Obesity and Metabolism Now, 0, , .	0.0	0
93	Early evidence for a GLPâ€receptor antagonist for the pharmacological management of post bariatric surgery reactive hypoglycaemia. Diabetes Obesity and Metabolism Now, 0, , .	0.0	Ο
94	C69. Percutaneous Balloon Pulmonary Valvuloplasty for Critical Pulmonary Stenosis Baby as A Challenging Management in Resource-Limited Hospital: A Case Report. European Heart Journal Supplements, 2021, 23, .	0.0	0